Blocking protein quality control to counter hereditary cancers.

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Cancer therapies targeting molecular chaperones and the ubiquitin-proteasome system are effective for certain cancers like multiple myeloma.
• Cancer cells' reliance on protein quality control (PQC) mechanisms creates a vulnerability exploitable by PQC inhibitors.
• The PQC system's
• better-safe-than-sorry
• approach can lead to degradation of functional proteins with minor structural defects.

Purpose of the Study:

• To review the potential of targeting the PQC system for treating hereditary cancer susceptibility syndromes.
• To explore how PQC inhibitors could avert or delay disease onset in inherited cancers caused by functional protein degradation.

Main Methods:

• Review of existing literature on PQC mechanisms, cancer therapies, and hereditary cancer syndromes.
• Analysis of how missense mutations in tumor suppressor genes affect protein stability and PQC targeting.
• Discussion of therapeutic strategies including chemical chaperones and PQC system inhibition.

Main Results:

• PQC inhibitors can induce a lethal proteotoxic crisis in cancer cells.
• In hereditary cancer syndromes, PQC can degrade functional mutant proteins, leading to loss-of-function phenotypes.
• Stabilizing these proteins or inhibiting PQC may prevent or delay disease manifestation.

Conclusions:

• Targeting the PQC system offers a dual therapeutic strategy for both established cancers and hereditary cancer susceptibility syndromes.
• Interventions aimed at modulating PQC present a promising avenue for novel cancer prevention and treatment strategies.